QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

Objective: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of...

Full description

Bibliographic Details
Main Authors:	Hiromi Okuyama, Seigo Nakamura, Sadako Akashi-Tanaka, Terumasa Sawada, Takashi Kuwayama, Satoko Handa, Yasuhisa Kato
Format:	Article
Language:	English
Published:	Galenos Publishing House 2018-10-01
Series:	European Journal of Breast Health
Subjects:	breast cancer therapy side effect quality of life patient support system
Online Access:	http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/qol-evaluation-of-nab-paclitaxel-and-docetaxel-for/42023

Similar Items

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
by: Hiraku Kokubu, et al.
Published: (2023-05-01)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
by: Dranitsaris G, et al.
Published: (2015-05-01)

nab-Paclitaxel for the treatment of pancreatic cancer
by: Kim G
Published: (2017-03-01)

Optimal Breast Density Characterization Using a Three-Dimensional Automated Breast Densitometry System
by: Reika Yoshida, et al.
Published: (2021-12-01)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
by: Rui Wan, et al.
Published: (2023-06-01)

Macular Cystoid Edema Induced by Nab-Paclitaxel
by: Sara Alves Pereira, et al.
Published: (2022-04-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
by: Xi Guo, MD, et al.
Published: (2020-03-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
by: Harjinder Singh MD, et al.
Published: (2023-11-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

Solubilization Methods for Paclitaxel and Docetaxel: An Overview
by: Fariba Pourkarim, et al.
Published: (2022-04-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
by: Shuling Chen, et al.
Published: (2023-03-01)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
by: Prakash Vishnu, et al.
Published: (2011-04-01)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
by: Vera eHirsh, et al.
Published: (2014-07-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
by: De Luca R, et al.
Published: (2018-06-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
by: Md Sazzad Hassan, et al.
Published: (2023-07-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
by: Jingjing Zhang, et al.
Published: (2023-03-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
by: Yoshioka K, et al.
Published: (2022-03-01)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
by: Hisashi Tanaka, et al.
Published: (2017-10-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
by: Masashi Sawada, et al.
Published: (2020-05-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report
by: Yu L, et al.
Published: (2024-04-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)

A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
by: Shetal A. Patel, et al.
Published: (2021-08-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
by: Anne Steins, et al.
Published: (2017-01-01)

Aqueous extract of Phragmitis rhizoma ameliorates myelotoxicity of docetaxel in vitro and in vivo
by: Jinhee Kim, et al.
Published: (2017-08-01)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialResearch in context
by: Tanios Bekaii-Saab, et al.
Published: (2023-04-01)

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
by: Zhang F, et al.
Published: (2022-02-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
by: Jiahui Shen, et al.
Published: (2023-02-01)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
by: Guillaume Joe Pegna, et al.
Published: (2023-02-01)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
by: Javier Martin-Broto, et al.
Published: (2022-10-01)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
by: Garry Ceccon, et al.
Published: (2020-01-01)